Shire jumps as Vyvanse drug helps it to beat earnings forecast

Strong demand for Shire (Xetra: S7E.DE - news) 's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12 percent, boosting the London-listed group's shares ahead of its $32 billion acquisition of U.S (Other OTC: UBGXF - news) . Sales of Vyvanse, a treatment for attention deficit hyperactivity disorder (ADHD), rose 22 percent, partly reflecting the drug's recent approval as a treatment for binge eating disorder (BED). "Shire is off to a strong start in 2016,"